Tom Phd

Q: What is Tom Phd email address?

Email Tom Phd at tom.phd@us.eisai.com. This email is the most updated Tom Phd email found in 2026.

Q: How to contact Tom Phd?

To contact Tom Phd send an email to tom.phd@us.eisai.com.

Principal Scientist (Oligonucleotides) at Eisai US | Cambridge, Massachusetts, United States

About Tom Phd

Tom, PhD, currently serves as a Principal Scientist at Eisai US, where he leverages his extensive background in analytical and instrumental chemistry to drive innovation in the field of oligonucleotide therapeutics. With a specialized focus on chromatographic techniques, including HPLC, IEX, SFC, and LC-MS, Tom has become a pivotal figure in the development of analytical and purification platforms for nucleic acids, particularly antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). His expertise extends to the analysis and purification of complex biomolecules such as peptides, lipids, and small molecules, utilizing a diverse array of techniques including reverse phase (RP), ion-pair reversed phase (IPRP), anion exchange (AEX), hydrophobic interaction chromatography (HIC), size exclusion chromatography (SEC), and multi-dimensional chromatography (MMC).

In his role, Tom has successfully led key projects that involve method development and the purification of chiral compounds using normal phase (NP) techniques, showcasing his versatility and depth of knowledge in both analytical chemistry and biochemistry. His leadership in the analytical group has not only streamlined processes but has also fostered a collaborative environment that encourages innovation and scientific rigor. Tom’s contributions are instrumental in advancing Eisai’s mission to develop groundbreaking therapies, as he continuously seeks to enhance the characterization and purification of nucleic acids, thereby ensuring the highest quality in drug development. His proficiency in cutting-edge technologies, including microfluidics and MALDI-TOF, positions him as a thought leader in the industry, driving forward the next generation of therapeutic solutions.

Tom Phd Work